|
2025
|
G/S
|
Shampoos and hair lotions for the treatment and prevention of head lice.. Anti-lice preparations;... |
|
|
G/S
|
Pharmaceutical preparations containing cefuroxime for the treatment of infections.. |
|
|
G/S
|
Pharmaceutical preparations containing fulvestrant; injections containing fulvestrant.. |
|
|
G/S
|
Pharmaceutical calcium preparations for human use.. |
|
|
G/S
|
Vitamins, trace minerals and nutritional supplements.. |
|
|
G/S
|
Pharmaceutical preparations containing naproxen.. |
|
|
G/S
|
Dermatological creams [non-medicated] for skin or mucous
membrane irritation, abrasions, cracks ... |
|
|
G/S
|
Pharmaceutical products; vitamin preparations; nutritional supplements.. |
|
|
G/S
|
Pharmaceutical preparations for the treatment of epilepsy.. |
|
2024
|
G/S
|
Vitamins, trace minerals and nutritional supplements. |
|
|
G/S
|
Medical plasters containing lidocaine.. |
|
|
G/S
|
Dental care preparations for animals; non-medicated hair
shampoos; shampoos for pets [non-medica... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of parkinson's disease and syndrome; transdermal pa... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of Parkinson's disease and syndrome; transdermal pa... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of Parkinson's
disease and syndrome; transdermal p... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of parkinson's
disease and syndrome; transdermal p... |
|
|
G/S
|
Pharmaceutical preparations; nutritional supplements. |
|
|
G/S
|
Dental care preparations for animals; Non-medicated hair shampoos; Shampoos for pets [non-medicat... |
|
|
Invention
|
Process for the preparation of androgen receptor antagonists and intermediates thereof. The prese... |
|
|
G/S
|
Pharmaceutical preparations for human use. |
|
|
G/S
|
Pharmaceutical preparations for human use for the treatment
of schizophrenia. |
|
|
G/S
|
Pharmaceutical preparations to treat respiratory disorders. Medical inhalers. |
|
|
Invention
|
Stable pharmaceutical compositions of a cyp11a1 inhibitor. The present invention relates to a pha... |
|
|
G/S
|
Pharmaceutical preparations. |
|
|
G/S
|
Pharmaceutical preparations. |
|
|
G/S
|
Pharmaceutical preparations.. |
|
|
Invention
|
2-phenoxy-1-(4-(alkylsulfonyl)piperidin-1-yl)ethan-1-one and 3-phenyl-1-(4-(alkylsulfonyl)piperid... |
|
|
G/S
|
Nutritional supplements containing iron.. |
|
|
G/S
|
Pharmaceutical preparations for the treatment of Parkinson's
disease and syndrome. |
|
|
G/S
|
Pharmaceutical preparations containing pregabalin; medical
and veterinary preparations containin... |
|
|
G/S
|
Pharmaceutical preparations containing pregabalin; medical and veterinary preparations containing... |
|
|
G/S
|
Pharmaceutical preparations for human use, namely, allergy
medication. |
|
|
Invention
|
Pyran derivatives as cyp11a1 (cytochrome p450 monooxygenase 11a1) inhibitors.
Compounds of formu... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of neurological and neurodevelopmental disorders.. |
|
|
G/S
|
Pharmaceutical preparations. Medical equipments. |
|
|
G/S
|
Pharmaceutical preparations; pharmaceutical preparations for the treatment and alleviation of ast... |
|
|
G/S
|
Pharmaceutical, veterinary and sanitary preparations; drugs
for medical use. |
|
|
G/S
|
Pharmaceutical preparations for the treatment of Parkinson's disease and syndrome. |
|
|
Invention
|
Androgen receptor antagonists for the treatment of patients with biochemical recurrence of hormon... |
|
|
Invention
|
Cbl-b inhibitors. 123 3 are as defined in claim 1, or a pharmaceutically acceptable salt thereof.... |
|
|
Invention
|
Process for the preparation of 3-(4,5-dichloro-2-(4-(trifluoromethoxy)phenoxy)benzamido)pyridine ... |
|
2023
|
Invention
|
Tasipimidine and cyp2d6 inhibitor combination treatment. The invention relates to co-administrati... |
|
|
Invention
|
Antibody discovery and development method. A method to introduce a mutation to a variable domain ... |
|
|
Invention
|
Use of levodopa, carbidopa and entacapone for treating parkinson's disease.
The present disclosu... |
|
|
Invention
|
A method for determining a physical state of a subject, a data processing apparatus and a system.... |
|
|
Invention
|
Novel salt forms of isochroman-imidazole structured alpha-2a adrenoceptor agonist. The present di... |
|
|
Invention
|
Novel sulfate salt forms of isochroman-imidazole structured alpha-2a adrenoceptor agonist. HH-imi... |
|
|
Invention
|
Novel sulfate salt forms of isochroman-imidazole structured alpha-2a adrenoceptor agonist. The pr... |
|
|
Invention
|
Pharmaceutical composition of a cyp11a1 inhibitor.
The present invention relates to a pharmaceut... |
|
|
Invention
|
Pharmaceutical composition of a cyp11a1 inhibitor. The present invention relates to a pharmaceuti... |
|
2022
|
Invention
|
Cyp11a1 inhibitors.
The present invention relates to a compound of formula (I) wherein A, B, R1,... |
|
|
Invention
|
Cyp11a1 inhibitors. 123455 are as defined in claim 1, or pharmaceutically acceptable salts thereo... |
|
|
Invention
|
Salt forms of a 4h-pyran-4-one structured cyp11 at inhibitor. The present invention relates to no... |
|
|
Invention
|
Cyp11a1 inhibitor for use in the treatment of prostate cancer. The invention relates to the use o... |
|
|
Invention
|
Process for the preparation of a cyp11a1 inhibitor and intermediates thereof.
The present invent... |
|
|
Invention
|
Process for the preparation of a cyp11a1 inhibitor and intermediates thereof. The present inventi... |
|
|
Invention
|
Tead inhibitors.
The present invention relates to a compound of formula (I)
The present invent... |
|
|
Invention
|
Tead inhibitors. The present invention relates to a compound of formula (I) wherein A, Z, L, R1, ... |
|
|
Invention
|
Tead inhibitors. 123453333 are as defined in claim 1, or a pharmaceutically acceptable salt there... |
|
|
Invention
|
Tasipimidine formulations and use thereof.
The present disclosure relates to a pharmaceutical co... |
|
|
Invention
|
Tasipimidine formulations and use thereof. The present disclosure relates to a pharmaceutical com... |
|
|
Invention
|
Novel salt forms of a 4h-pyran-4-one structured cyp11a1 inhibitor.
The present invention relates... |
|
|
Invention
|
Solid forms of a 4h-pyran-4-one structured cyp11a1 inhibitor.
The present invention relates to n... |
|
|
Invention
|
Inhaler |
|
2021
|
Invention
|
Chimeric antigen receptor (car) spacer modifications enhance car t cell functionality.
The prese... |
|
|
Invention
|
2,3-dihydro-4h-benzo[b][1,4]oxazin-4-yl)(5-(phenyl)-pyridin-3-yl)methanone derivatives and simila... |
|
|
Invention
|
Cyp11a1 inhibitors.
The present invention relates to compounds of formula (I) and (II)
The pre... |
|
|
Invention
|
Method for the preparation of androgen receptor antagonists and intermediates thereof.
The prese... |
|
|
Invention
|
Stable pharmaceutical compositions of ropinirole.
The invention relates to pharmaceutical aqueou... |
|
2020
|
Invention
|
Pyridine oxynitride, preparation method therefor and use thereof.
The present invention belongs ... |
|
|
Invention
|
Methods for administering (r)-n-[4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)phenyl]acetamide.
The... |
|
|
Invention
|
Pharmaceutical composition of darolutamide.
The present invention relates to a pharmaceutical co... |
|
|
Invention
|
Packaging box |
